Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 16
2022 13
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Multicenter study of the natural history and therapeutic responses of patients with chikungunya, focusing on acute and chronic musculoskeletal manifestations - a study protocol from the clinical and applied research in Chikungunya (REPLICK network).
da Silva Duarte G, Jones AD, de Goes Cavalcanti LP, de Melo Rêgo MJB, Ribeiro GS, Boyton RJ, Pereira DB, Croda JHR, Costa FTM, Duarte AP, Consolaro MEL, Stabeli RG, Negrão FJ, Proenca-Modena JL, Villalobos-Salcedo JM, da Rocha Castelar Pinheiro G, de Barros Albuquerque AP, de Almeida Barreto FK, Moreira J, Ferrari IC, Évora PM, da Silva VRS, Lacerda MVG, Altmann DM; REPLICK network; Siqueira AM. da Silva Duarte G, et al. BMC Infect Dis. 2023 Jul 28;23(1):499. doi: 10.1186/s12879-023-08292-y. BMC Infect Dis. 2023. PMID: 37507666 Free PMC article.
Imprinted hybrid immunity against XBB reinfection.
Boyton RJ, Altmann DM. Boyton RJ, et al. Lancet Infect Dis. 2023 Jul;23(7):764-765. doi: 10.1016/S1473-3099(23)00138-X. Epub 2023 Mar 13. Lancet Infect Dis. 2023. PMID: 36924785 Free PMC article. No abstract available.
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z, Le K, Zhou X, Alexander JL, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald TJ, Lamb CA, Sebastian S, Kok K, Lees CW, Hart AL, Pollok RC, Boyton RJ, Altmann DM, Pollock KM, Goodhand JR, Kennedy NA, Ahmad T, Powell N; CLARITY study investigators. Liu Z, et al. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):145-156. doi: 10.1016/S2468-1253(22)00389-2. Epub 2022 Dec 5. Lancet Gastroenterol Hepatol. 2023. PMID: 36481043 Free PMC article.
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.
Liu Z, Alexander JL, Lin KW; VIP Study Investigators; Ahmad T, Pollock KM, Powell N. Liu Z, et al. Gastroenterology. 2023 Feb;164(2):300-303.e3. doi: 10.1053/j.gastro.2022.10.010. Epub 2022 Oct 19. Gastroenterology. 2023. PMID: 36270334 Free PMC article. No abstract available.
Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection.
Captur G, Moon JC, Topriceanu CC, Joy G, Swadling L, Hallqvist J, Doykov I, Patel N, Spiewak J, Baldwin T, Hamblin M, Menacho K, Fontana M, Treibel TA, Manisty C, O'Brien B, Gibbons JM, Pade C, Brooks T, Altmann DM, Boyton RJ, McKnight Á, Maini MK, Noursadeghi M, Mills K, Heywood WE; UK COVIDsortium Investigators. Captur G, et al. EBioMedicine. 2022 Nov;85:104293. doi: 10.1016/j.ebiom.2022.104293. Epub 2022 Sep 28. EBioMedicine. 2022. PMID: 36182629 Free PMC article.
Serum biomarkers associated with SARS-CoV-2 severity.
de Morais Batista F, Puga MAM, da Silva PV, Oliveira R, Dos Santos PCP, da Silva BO, Tatara MB, Tsuha DH, Dos Santos Pires MA, Gonçalves CCM, Pessoa E Silva R, Ferreira NT, de Barros Albuquerque AP, da Silva Duarte G, Consolaro MEL, Negrão FJ, Ferrari IC, de Goes Cavalcanti LP, Trinta KS, Ribeiro GS, de Melo Rêgo MJB, Boyton RJ, Siqueira AM, Altmann DM, Croda J. de Morais Batista F, et al. Sci Rep. 2022 Sep 26;12(1):15999. doi: 10.1038/s41598-022-20062-5. Sci Rep. 2022. PMID: 36163447 Free PMC article.
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Alexander JL, Liu Z, Muñoz Sandoval D, Reynolds C, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Anand N, Nice R, Bewshea C, D'Mello A, Constable L, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Goodhand JR, Hart AL, Lees CW, Boyton RJ, Kennedy NA, Ahmad T, Powell N; VIP study investigators. Alexander JL, et al. Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1005-1015. doi: 10.1016/S2468-1253(22)00274-6. Epub 2022 Sep 9. Lancet Gastroenterol Hepatol. 2022. PMID: 36088954 Free PMC article.
Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response.
Doykov I, Baldwin T, Spiewak J, Gilmour KC, Gibbons JM, Pade C, Reynolds CJ, Áine McKnight, Noursadeghi M, Maini MK, Manisty C, Treibel T, Captur G, Fontana M, Boyton RJ, Altmann DM, Brooks T, Semper A; UK COVIDsortium Investigators; Moon JC, Kevin Mills, Heywood WE. Doykov I, et al. Cell Rep Methods. 2022 Sep 19;2(9):100279. doi: 10.1016/j.crmeth.2022.100279. Epub 2022 Aug 12. Cell Rep Methods. 2022. PMID: 35975199 Free PMC article.
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
Kennedy NA, Janjua M, Chanchlani N, Lin S, Bewshea C, Nice R, McDonald TJ, Auckland C, Harries LW, Davies M, Michell S, Kok KB, Lamb CA, Smith PJ, Hart AL, Pollok RC, Lees CW, Boyton RJ, Altmann DM, Sebastian S, Powell N, Goodhand JR, Ahmad T. Kennedy NA, et al. Gut. 2023 Feb;72(2):295-305. doi: 10.1136/gutjnl-2022-327570. Epub 2022 Jul 28. Gut. 2023. PMID: 35902214
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure.
Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Muñoz Sandoval D, Pieper FP, Butler DK, Liu S, Joy G, Forooghi N, Treibel TA, Manisty C, Moon JC; COVIDsortium Investigators§; COVIDsortium Immune Correlates Network§; Semper A, Brooks T, McKnight Á, Altmann DM, Boyton RJ, Abbass H, Abiodun A, Alfarih M, Alldis Z, Altmann DM, Amin OE, Andiapen M, Artico J, Augusto JB, Baca GL, Bailey SNL, Bhuva AN, Boulter A, Bowles R, Boyton RJ, Bracken OV, O'Brien B, Brooks T, Bullock N, Butler DK, Captur G, Carr O, Champion N, Chan C, Chandran A, Coleman T, Couto de Sousa J, Couto-Parada X, Cross E, Cutino-Moguel T, D'Arcangelo S, Davies RH, Douglas B, Di Genova C, Dieobi-Anene K, Diniz MO, Ellis A, Feehan K, Finlay M, Fontana M, Forooghi N, Francis S, Gibbons JM, Gillespie D, Gilroy D, Hamblin M, Harker G, Hemingway G, Hewson J, Heywood W, Hickling LM, Hicks B, Hingorani AD, Howes L, Itua I, Jardim V, Lee WJ, Jensen M, Jones J, Jones M, Joy G, Kapil V, Kelly C, Kurdi H, Lambourne J, Lin KM, Liu S, Lloyd A, Louth S, Maini MK, Mandadapu V, Manisty C, McKnight Á, Menacho K, Mfuko C, Mills K, Millward S, Mitchelmore O, Moon C, Moon J, Muñoz Sandoval D, Murray SM, Noursadeghi M, Otter A, Pade C, Pa… See abstract for full author list ➔ Reynolds CJ, et al. Science. 2022 Jul 15;377(6603):eabq1841. doi: 10.1126/science.abq1841. Epub 2022 Jul 15. Science. 2022. PMID: 35699621 Free PMC article.
31 results